查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2026936

阿斯匹靈市場預測至2034年：按產品、劑型、通路和地區分類的全球分析

Aspirin Drug Market Forecasts to 2034 - Global Analysis By Product (Ecotrin, Bufferin, Generic Aspirin and Other Products), Dosage Form, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球阿斯匹靈藥品市場規模將達到 29 億美元，並在預測期內以 5.4% 的複合年成長率成長，到 2034 年將達到 45 億美元。

阿斯匹靈藥品市場涵蓋含有乙醯水楊酸（俗稱阿斯匹靈）的藥物。阿斯匹靈是一種廣泛使用的藥物，具有鎮痛、抗發炎和退燒作用。阿斯匹靈屬於非類固醇消炎劑(NSAID)，用於疼痛管理、消炎和退燒。此外，阿斯匹靈還具有抗凝血特性，有助於預防心臟病發作和中風等心血管事件。

根據美國疾病管制與預防中心 (CDC) 發布的一份報告，美國四分之一的成年人被醫生診斷出患有關節炎，總計約 5,850 萬人。

對心血管健康的益處

阿斯匹靈因其抗血小板特性而廣為人知，能夠降低包括心臟病發作和中風在內的心血管事件風險。該藥物透過抑制血栓形成發揮作用，這是預防血管阻塞（可能導致嚴重心血管疾病）的關鍵因素。醫生通常會為有心血管疾病史或高危險群開立阿斯匹靈作為預防措施。此外，阿斯匹靈在治療心肌梗塞等急性疾病的有效性進一步凸顯了其在醫療保健領域的重要性。隨著人們對預防醫學重要性以及阿斯匹靈在降低心血管風險方面作用的認知不斷提高，由於其已證實的挽救生命的心血管健康益處，阿斯匹靈的需求持續成長。

對潛在副作用的認知提高

隨著有關阿斯匹靈副作用的資訊日益普及，醫護人員和消費者在使用阿斯匹靈時都變得更加謹慎。胃腸道併發症（例如潰瘍和出血）的風險早已是眾所周知。這種意識的提高促使醫護人員更謹慎地開立處方，並考慮使用副作用較少的替代藥物。然而，隨著患者對潛在風險的了解加深，這開始影響他們使用阿斯匹靈的意願，尤其是在長期服用的情況下。

全球老化

隨著全球人口老化，與老齡化相關的健康問題，尤其是心血管疾病的盛行率不斷上升。阿斯匹靈因其對心血管系統的益處而聞名，並被廣泛用於預防老年人心臟病和中風。由於老年人發生血栓事件的風險通常較高，阿斯匹靈在他們的醫療保健計劃中發揮著至關重要的作用。此外，隨著老齡化，我們可能更容易患上疼痛和發炎性疾病，這進一步增加了對阿斯匹靈作為鎮痛和抗發炎藥物的需求。

出血風險

阿斯匹靈的抗凝血作用對於預防心血管事件至關重要，但它也會增加出血併發症的風險。對於接受手術的患者或本身就有出血性疾病的患者，這種擔憂尤其重要。醫護人員在開立此藥時必須謹慎判斷，權衡其益處和潛在副作用之間的微妙平衡。然而，對出血事件的擔憂可能會導致醫生在開立阿斯匹靈時猶豫不決，尤其是在某些特定患者群體中，必須仔細評估其風險獲益比。

新冠疫情的影響：

隨著人們對新冠肺炎患者潛在心血管併發症的認知不斷提高，阿斯匹靈作為預防措施的處方量激增。阿斯匹靈具有抗血小板聚集作用，可望降低重症新冠肺炎患者發生血栓事件的風險。然而，疫情期間醫療服務的中斷、病患就醫需求的轉變以及處方模式的變化，都對全球市場造成了影響。

在預測期內，Ecotrin細分市場預計將佔據最大的市場佔有率。

在預測期內，專注於腸溶阿斯匹靈製劑的Ecotrin業務板塊佔據了全球阿斯匹靈市場最大的佔有率。 Ecotrin品牌以其腸溶阿斯匹靈產品而聞名，致力於解決阿斯匹靈服用中常見的胃腸道副作用問題。此外，腸溶包衣使阿斯匹靈能夠順利通過胃部而不會引起刺激，其活性成分在腸道內釋放並被吸收。這項創新技術降低了胃潰瘍和出血的風險，並提高了需要長期服用阿斯匹靈患者的藥物耐受性。

在預測期內，咀嚼片細分市場預計將呈現最高的複合年成長率。

隨著市場對患者便利性和用藥依從性的日益重視，咀嚼型阿斯匹靈片應運而生，為患者提供了一種比傳統片劑更便捷、更易使用的替代方案。這種創新產品尤其吸引那些吞嚥藥片有困難的人群，例如老年人和兒童。咀嚼片滿足了人們對更便利、更舒適的用藥體驗的需求，有助於提高患者的用藥依從性。此外，咀嚼型阿斯匹靈片口感宜人，也使其成為尋求非處方藥人士的理想選擇。

市佔率最大的地區：

隨著人們對心血管健康的日益關注、慢性病盛行率的上升以及人口老化，預計亞太地區將在預測期內佔據最大的市場佔有率。隨著該地區各國經濟發展和都市化進程的推進，人們的生活方式正在改變，久坐不動的生活方式和飲食習慣的改變已成為人們關注的健康問題。此外，心血管疾病盛行率的上升，以及人們對阿斯匹靈預防作用的認知不斷加深，都推動了對這種藥物的需求。

預計複合年成長率最高的地區：

在歐洲，人口老化和心血管疾病的高發推動了對阿斯匹靈的需求，使其成為預防心臟病和中風的有效手段，從而帶來了盈利的成長。該地區重視實證醫學，並擁有健全的法規結構，這為阿斯匹靈在各種臨床環境中的持續處方和使用提供了支持。此外，心血管健康一直是歐洲醫療保健體系的重點，阿斯匹靈作為一種經濟有效且廣泛可用的藥物，與該地區管理和預防心血管疾病的努力相契合，極大地促進了該地區阿斯匹靈市場的蓬勃發展。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球阿斯匹靈市場：依產品分類

  • 生態素
  • 緩衝劑
  • 非專利阿斯匹林
  • 其他產品

第6章 全球阿斯匹靈市場：以劑型分類

  • 腸溶片
  • 咀嚼片
  • 可溶片或發泡
  • 其他劑型

第7章 全球阿斯匹靈市場：依通路分類

  • 藥局/藥局
  • 線上零售商
  • 雜貨店和超級市場
  • 批發商
  • 其他分銷管道

第8章 全球阿斯匹靈市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Cadila Healthcare Limited
  • Alembic Pharmaceuticals Limited
  • GlaxoSmithKline Consumer Healthcare Ltd
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd
  • Abbott Laboratories
  • Aspen Pharmacare Holdings Limited
  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Pfizer Inc
  • Bayer AG
  • Roche Holding AG
Product Code: SMRC24714

According to Stratistics MRC, the Global Aspirin Drug Market is accounted for $2.9 billion in 2026 and is expected to reach $4.5 billion by 2034 growing at a CAGR of 5.4% during the forecast period. The aspirin drug market encompasses pharmaceutical products containing acetylsalicylic acid, commonly known as aspirin, which is a widely used medication with analgesic, anti-inflammatory, and antipyretic properties. Aspirin belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is utilized for pain relief, reduction of inflammation, and fever management. Additionally, aspirin is recognized for its anticoagulant effects, contributing to its application in preventing cardiovascular events such as heart attacks and strokes.

According to a report shared by the Centers for Disease Control and Prevention, a US-based national public health agency, 1 in 4 adults in the US were suffering from doctor-diagnosed arthritis, which is almost 58.5 million people.

Market Dynamics:

Driver:

Cardiovascular health benefits

Aspirin, with its antiplatelet properties, is widely recognized for its ability to reduce the risk of cardiovascular events, including heart attacks and strokes. The drug works by inhibiting the formation of blood clots, a crucial factor in preventing blockages in blood vessels that can lead to severe cardiovascular issues. Physicians often prescribe aspirin as a preventive measure for individuals with a history of cardiovascular diseases or those at higher risk. Additionally, the drug's efficacy in managing acute conditions, such as myocardial infarction, further underscores its importance in cardiovascular care. As awareness grows regarding the significance of preventive healthcare and the role of aspirin in reducing cardiovascular risks, the demand for aspirin continues to be driven by its well-established and life-saving cardiovascular health benefits.

Restraint:

Growing awareness of potential side effects

As information about the adverse effects associated with aspirin becomes more widely disseminated, both healthcare professionals and consumers exercise increased caution in its usage. The risk of gastrointestinal complications, such as ulcers and bleeding, is a well-documented concern. This heightened awareness has led to more prudent prescribing practices by healthcare providers, who may consider alternative medications with a more favorable side effect profile. However, patients are becoming more informed about the potential risks, impacting their willingness to use aspirin, particularly for long-term applications.

Opportunity:

Global aging population

With an increasing number of elderly individuals worldwide, there is a higher prevalence of age-related health conditions, particularly cardiovascular diseases. Aspirin, known for its cardiovascular benefits, is commonly prescribed to the aging demographic as a preventive measure against heart attacks and strokes. The elderly population often experiences a higher risk of thrombotic events, making aspirin a key component in their healthcare regimen. Additionally, as people age, they may be more susceptible to conditions associated with pain and inflammation, further contributing to the demand for aspirin as an analgesic and anti-inflammatory medication.

Threat:

Risk of bleeding

While aspirin's anticoagulant properties are crucial for preventing cardiovascular events, they concurrently elevate the risk of bleeding complications. This concern is particularly relevant for individuals undergoing surgical procedures or those with pre-existing bleeding disorders. The delicate balance between aspirin's benefits and potential adverse effects requires careful consideration by healthcare professionals when prescribing the drug. However, the fear of bleeding events may lead to hesitancy in prescribing aspirin, especially in certain patient populations where the risk-benefit ratio must be meticulously assessed.

Covid-19 Impact:

The increased awareness of potential cardiovascular complications in COVID-19 patients has led to a surge in aspirin prescriptions as a preventive measure. As aspirin exhibits antiplatelet properties, it is often considered for its potential role in mitigating the risk of thrombotic events associated with severe COVID-19 cases. However, disruptions in healthcare services, shifts in patient priorities, and altered prescribing patterns during the pandemic have influenced the market globally.

The ecotrin segment is expected to be the largest during the forecast period

Ecotrin segment commanded the largest market share of aspirin drug globally over the projected period due to its focus on enteric-coated aspirin formulations. Ecotrin, a brand recognized for its enteric-coated aspirin products, addresses the issue of gastrointestinal side effects commonly associated with aspirin use. Furthermore, the enteric coating enables the aspirin to pass through the stomach without causing irritation, releasing the medication in the intestines where absorption occurs. This innovation reduces the risk of stomach ulcers and bleeding, enhancing the drug's tolerability for patients requiring long-term aspirin therapy.

The chewable tablets segment is expected to have the highest CAGR during the forecast period

With a growing market trend toward patient convenience and adherence, chewable aspirin tablets offer a more palatable and user-friendly alternative to traditional pill forms. This innovation appeals to individuals who may have difficulty swallowing pills, including the elderly and children. The Chewable Tablets segment is capitalizing on the demand for a more accessible and enjoyable medication experience, contributing to increased patient compliance. Furthermore, the pleasant taste of chewable aspirin tablets makes them a favorable choice for individuals seeking over-the-counter pain relief options.

Region with largest share:

Due to the rising awareness of cardiovascular health, a surge in chronic diseases, and an expanding aging population, Asia Pacific region is expected to hold largest market share over the forecast period. As countries in the region undergo economic development and urbanization, lifestyles are evolving, leading to an increase in sedentary habits and dietary changes that contribute to health concerns. Additionally, the growing prevalence of cardiovascular diseases in tandem with an increasing understanding of aspirin's preventive benefits is fostering a higher demand for this medication.

Region with highest CAGR:

Europe is expected to hold profitable growth owing to the region's aging population, coupled with a high prevalence of cardiovascular diseases, has propelled the demand for aspirin as a preventive measure against heart attacks and strokes. The region's emphasis on evidence-based medicine and a strong regulatory framework supports the continued prescription and use of aspirin in various clinical contexts. Additionally, as cardiovascular health remains a primary focus in European healthcare systems, aspirin's role as a cost-effective and widely available medication aligns with the region's commitment to managing and preventing cardiovascular diseases, thereby contributing significantly to the flourishing aspirin drug market in the region.

Key players in the market

Some of the key players in Aspirin Drug market include Cadila Healthcare Limited, Alembic Pharmaceuticals Limited, GlaxoSmithKline Consumer Healthcare Ltd, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd, Abbott Laboratories, Aspen Pharmacare Holdings Limited, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Novartis International AG, Pfizer Inc, Bayer AG and Roche Holding AG.

Key Developments:

In December 2023, Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical Co Ltd, has entered into a licensing agreement to co-develop and commercialise Leuprolide Acetate for Depot Suspension in six dosage strengths for the United States (US) market, the company in a regulatory filing with the BSE. The terms of the agreement will result in Zydus assuming full responsibility for the clinical development and commercialisation in the US market. Daewoong, on the other hand, will be responsible for the pre-clinical studies, production, and supply of the product.

In March 2023, Ahmedabad-based Cadila Pharmaceuticals has signed a Memorandum of Understanding (MoU) with the government of Gujarat to invest Rs 1,000 crore in different existing projects. The MoU was signed in Gandhinagar between Industries Commissioner Rahul Gupta on behalf of the government of Gujarat and Cadila Pharmaceuticals COO, Mitul Dave, under the Government of Gujarat's "Atma Nirbhar Gujarat Schemes for Assistance to Industries".

Products Covered:

  • Ecotrin
  • Bufferin
  • Generic Aspirin
  • Other Products

Dosage Forms Covered:

  • Enteric-Coated Tablets
  • Chewable Tablets
  • Dissolvable or Effervescent Tablets
  • Other Dosage Forms

Distribution Channels Covered:

  • Pharmacies and Drugstores
  • Online Retailers
  • Grocery Stores and Supermarkets
  • Wholesale Distributors
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Aspirin Drug Market, By Product

  • 5.1 Introduction
  • 5.2 Ecotrin
  • 5.3 Bufferin
  • 5.4 Generic Aspirin
  • 5.5 Other Products

6 Global Aspirin Drug Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Enteric-Coated Tablets
  • 6.3 Chewable Tablets
  • 6.4 Dissolvable or Effervescent Tablets
  • 6.5 Other Dosage Forms

7 Global Aspirin Drug Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Pharmacies and Drugstores
  • 7.3 Online Retailers
  • 7.4 Grocery Stores and Supermarkets
  • 7.5 Wholesale Distributors
  • 7.6 Other Distribution Channels

8 Global Aspirin Drug Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Cadila Healthcare Limited
  • 10.2 Alembic Pharmaceuticals Limited
  • 10.3 GlaxoSmithKline Consumer Healthcare Ltd
  • 10.4 Takeda Pharmaceutical Company Limited
  • 10.5 Torrent Pharmaceuticals Ltd
  • 10.6 Abbott Laboratories
  • 10.7 Aspen Pharmacare Holdings Limited
  • 10.8 Dr. Reddy's Laboratories Ltd
  • 10.9 Sun Pharmaceutical Industries Ltd
  • 10.10 Teva Pharmaceutical Industries Ltd
  • 10.11 Novartis International AG
  • 10.12 Pfizer Inc
  • 10.13 Bayer AG
  • 10.14 Roche Holding AG

List of Tables

  • Table 1 Global Aspirin Drug Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Aspirin Drug Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Aspirin Drug Market Outlook, By Ecotrin (2023-2034) ($MN)
  • Table 4 Global Aspirin Drug Market Outlook, By Bufferin (2023-2034) ($MN)
  • Table 5 Global Aspirin Drug Market Outlook, By Generic Aspirin (2023-2034) ($MN)
  • Table 6 Global Aspirin Drug Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 7 Global Aspirin Drug Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 8 Global Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 9 Global Aspirin Drug Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 10 Global Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2023-2034) ($MN)
  • Table 11 Global Aspirin Drug Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 12 Global Aspirin Drug Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 13 Global Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2023-2034) ($MN)
  • Table 14 Global Aspirin Drug Market Outlook, By Online Retailers (2023-2034) ($MN)
  • Table 15 Global Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2023-2034) ($MN)
  • Table 16 Global Aspirin Drug Market Outlook, By Wholesale Distributors (2023-2034) ($MN)
  • Table 17 Global Aspirin Drug Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 18 North America Aspirin Drug Market Outlook, By Country (2023-2034) ($MN)
  • Table 19 North America Aspirin Drug Market Outlook, By Product (2023-2034) ($MN)
  • Table 20 North America Aspirin Drug Market Outlook, By Ecotrin (2023-2034) ($MN)
  • Table 21 North America Aspirin Drug Market Outlook, By Bufferin (2023-2034) ($MN)
  • Table 22 North America Aspirin Drug Market Outlook, By Generic Aspirin (2023-2034) ($MN)
  • Table 23 North America Aspirin Drug Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 24 North America Aspirin Drug Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 25 North America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 26 North America Aspirin Drug Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 27 North America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2023-2034) ($MN)
  • Table 28 North America Aspirin Drug Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 29 North America Aspirin Drug Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 30 North America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2023-2034) ($MN)
  • Table 31 North America Aspirin Drug Market Outlook, By Online Retailers (2023-2034) ($MN)
  • Table 32 North America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2023-2034) ($MN)
  • Table 33 North America Aspirin Drug Market Outlook, By Wholesale Distributors (2023-2034) ($MN)
  • Table 34 North America Aspirin Drug Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 35 Europe Aspirin Drug Market Outlook, By Country (2023-2034) ($MN)
  • Table 36 Europe Aspirin Drug Market Outlook, By Product (2023-2034) ($MN)
  • Table 37 Europe Aspirin Drug Market Outlook, By Ecotrin (2023-2034) ($MN)
  • Table 38 Europe Aspirin Drug Market Outlook, By Bufferin (2023-2034) ($MN)
  • Table 39 Europe Aspirin Drug Market Outlook, By Generic Aspirin (2023-2034) ($MN)
  • Table 40 Europe Aspirin Drug Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 41 Europe Aspirin Drug Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 42 Europe Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 43 Europe Aspirin Drug Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 44 Europe Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2023-2034) ($MN)
  • Table 45 Europe Aspirin Drug Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 46 Europe Aspirin Drug Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 47 Europe Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2023-2034) ($MN)
  • Table 48 Europe Aspirin Drug Market Outlook, By Online Retailers (2023-2034) ($MN)
  • Table 49 Europe Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2023-2034) ($MN)
  • Table 50 Europe Aspirin Drug Market Outlook, By Wholesale Distributors (2023-2034) ($MN)
  • Table 51 Europe Aspirin Drug Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 52 Asia Pacific Aspirin Drug Market Outlook, By Country (2023-2034) ($MN)
  • Table 53 Asia Pacific Aspirin Drug Market Outlook, By Product (2023-2034) ($MN)
  • Table 54 Asia Pacific Aspirin Drug Market Outlook, By Ecotrin (2023-2034) ($MN)
  • Table 55 Asia Pacific Aspirin Drug Market Outlook, By Bufferin (2023-2034) ($MN)
  • Table 56 Asia Pacific Aspirin Drug Market Outlook, By Generic Aspirin (2023-2034) ($MN)
  • Table 57 Asia Pacific Aspirin Drug Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 58 Asia Pacific Aspirin Drug Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 59 Asia Pacific Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 60 Asia Pacific Aspirin Drug Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 61 Asia Pacific Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2023-2034) ($MN)
  • Table 62 Asia Pacific Aspirin Drug Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 63 Asia Pacific Aspirin Drug Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 64 Asia Pacific Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2023-2034) ($MN)
  • Table 65 Asia Pacific Aspirin Drug Market Outlook, By Online Retailers (2023-2034) ($MN)
  • Table 66 Asia Pacific Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2023-2034) ($MN)
  • Table 67 Asia Pacific Aspirin Drug Market Outlook, By Wholesale Distributors (2023-2034) ($MN)
  • Table 68 Asia Pacific Aspirin Drug Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 69 South America Aspirin Drug Market Outlook, By Country (2023-2034) ($MN)
  • Table 70 South America Aspirin Drug Market Outlook, By Product (2023-2034) ($MN)
  • Table 71 South America Aspirin Drug Market Outlook, By Ecotrin (2023-2034) ($MN)
  • Table 72 South America Aspirin Drug Market Outlook, By Bufferin (2023-2034) ($MN)
  • Table 73 South America Aspirin Drug Market Outlook, By Generic Aspirin (2023-2034) ($MN)
  • Table 74 South America Aspirin Drug Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 75 South America Aspirin Drug Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 76 South America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 77 South America Aspirin Drug Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 78 South America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2023-2034) ($MN)
  • Table 79 South America Aspirin Drug Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 80 South America Aspirin Drug Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 81 South America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2023-2034) ($MN)
  • Table 82 South America Aspirin Drug Market Outlook, By Online Retailers (2023-2034) ($MN)
  • Table 83 South America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2023-2034) ($MN)
  • Table 84 South America Aspirin Drug Market Outlook, By Wholesale Distributors (2023-2034) ($MN)
  • Table 85 South America Aspirin Drug Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 86 Middle East & Africa Aspirin Drug Market Outlook, By Country (2023-2034) ($MN)
  • Table 87 Middle East & Africa Aspirin Drug Market Outlook, By Product (2023-2034) ($MN)
  • Table 88 Middle East & Africa Aspirin Drug Market Outlook, By Ecotrin (2023-2034) ($MN)
  • Table 89 Middle East & Africa Aspirin Drug Market Outlook, By Bufferin (2023-2034) ($MN)
  • Table 90 Middle East & Africa Aspirin Drug Market Outlook, By Generic Aspirin (2023-2034) ($MN)
  • Table 91 Middle East & Africa Aspirin Drug Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 92 Middle East & Africa Aspirin Drug Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 93 Middle East & Africa Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 94 Middle East & Africa Aspirin Drug Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 95 Middle East & Africa Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2023-2034) ($MN)
  • Table 96 Middle East & Africa Aspirin Drug Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 97 Middle East & Africa Aspirin Drug Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 98 Middle East & Africa Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2023-2034) ($MN)
  • Table 99 Middle East & Africa Aspirin Drug Market Outlook, By Online Retailers (2023-2034) ($MN)
  • Table 100 Middle East & Africa Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2023-2034) ($MN)
  • Table 101 Middle East & Africa Aspirin Drug Market Outlook, By Wholesale Distributors (2023-2034) ($MN)
  • Table 102 Middle East & Africa Aspirin Drug Market Outlook, By Other Distribution Channels (2023-2034) ($MN)